Latest Breaking News On - Phase 3 clear study nct02811861 - Page 1 : comparemela.com

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

United statesLenvatinib lenvimaInternational metastaticKidney cancer research summitDatabase consortiumMemorial sloan kettering cancer centerCancer researchWestern europeNorth americaRobertj motzerLenvatinib pembrolizumabPhase 3 clear study nct02811861Renal cell carcinoma2023 kidney cancer research summit